

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Heroes and pillars of rheumatology

- 1625** EULAR 75-year anniversary: commentaries on *ARD* papers from 25 years ago
K L Hyrich

Recommendations

- 1628** EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update
R B M Landewé, F P B Kroon, A Alunno, A Najm, J W J Bijlsma, G-R R Burmester, R Caporali, B Combe, R Conway, J R Curtis, O Elkayam, L Gossec, M W Heijstek, L Haupt, A Iagnocco, J D Isaacs, I Á Juhász, S Makri, X Mariette, I B McInnes, P Mehta, U Mueller-Ladner, H Schulze-Koops, J S Smolen, D Wiek, K L Winthrop, V Navarro-Compán, P M Machado

- 1640** EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology
A Najm, F Costantino, S Alivernini, A Alunno, E Bianchi, J Bignall, B Boyce, J D Cañete, F Carubbi, P Durez, J E Fonseca, S A Just, R Largo, A Manzo, M Maybury, E Naredo, C Orr, C Pitzalis, F Rivellese, V C Romão, J van Rompay, S W Tas, D J Veale, M-A D'Agostino, A Filer

Criteria

- 1647** 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
C Ponte, P C Grayson, J C Robson, R Suppiah, K B Gribbons, A Judge, A Craven, S Khalid, A Hutchings, R A Watts, P A Merkel, R A Luqmani, For the DCVAS Study Group
- 1654** 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis
P C Grayson, C Ponte, R Suppiah, J C Robson, K B Gribbons, A Judge, A Craven, S Khalid, A Hutchings, D Danda, R A Luqmani, R A Watts, P A Merkel, For the DCVAS Study Group

Rheumatoid arthritis

- 1661** Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
E Feist, S Fatenejad, S Grishin, E Korneva, M E Luggen, E Nasonov, M Samsonov, J S Smolen, R M Fleischmann

- 1669** Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis
M Cheng, Y Zhao, Y Cui, C Zhong, Y Zha, S Li, G Cao, M Li, L Zhang, K Ning, J Han

Spondyloarthritis

- 1678** Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis
T S H Kwok, M Sutton, D Pereira, R J Cook, V Chandran, N Haroon, R D Inman, D D Gladman

Systemic lupus erythematosus

- 1685** Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
J Y Humrich, P Cacoub, M Rosenzwajg, F Pitoiset, H P PHAM, J Guidoux, D Leroux, T Vazquez, G Riemekasten, J S Smolen, G Tsokos, D Klatzmann
- 1695** Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN- α
A Mathian, P Breillat, K Dorgham, P Bastard, C Charre, R Lhote, P Quentric, Q Moyon, A-A Mariaggi, S Mouries-Martin, C Mellot, F Anna, J Haroche, F Cohen-Aubart, D Sterlin, N Zahr, A Gervais, T Le Voyer, L Bizien, Q Amiot, M Pha, M Hié, F Chasset, H Yssel, M Miyara, P Charneau, P Ghillani-Dalbin, J-L Casanova, F Rozenberg, Z Amoura, G Gorochov

- 1704** Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV
M M Bolognesi, G Capitoli, S Galimberti, G Cattoretti, I Bajema, J A Bruijn, H T Cook, L-H Noel, F Pagni, F Ferrario, M Wester Trejo, V L Imperio

- 1712** Loss-of-function variants in *SAT1* cause X-linked childhood-onset systemic lupus erythematosus
L Xu, J Zhao, Q Sun, X Xu, L Wang, T Liu, Y Wu, J Zhu, L Geng, Y Deng, A Awgulewitsch, D L Kamen, J C Oates, P Raj, E K Wakeland, R H Scofield, J M Guthridge, J A James, B H Hahn, D K McCurdy, F Wang, M Zhang, W Tan, G S Gilkeson, B P Tsao

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>



Member since 2008

J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
<http://publicationethics.org/>



When you have finished with this please recycle it

Systemic sclerosis

- 1722** Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSIS-ON



Y Allano, M C Vonk, O Distler, A Azuma, M D Mayes, M Gahlemann, A James, V Kohlbrenner, M Alves, D Khanna, K B Highland, on behalf of the SENSIS-ON trial investigators

Autoinflammatory disorders

- 1730** Distinct immune-effector and metabolic profile of CD8⁺ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors



K Benesova, F V Kraus, R A Carvalho, H Lorenz, C H Hörth, J Günther, K D Klika, J Graf, L Diekmann, T Schank, P Christopoulos, J C Hassel, H-M Lorenz, M Souto-Carneiro

Epidemiology

- 1742** Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave

Y Kawano, N J Patel, X Wang, C E Cook, K M M Vanni, E N Kowalski, E P Banasiak, C Qian, M DiIorio, T Y-T Hsu, M E Weinblatt, D J Todd, Z S Wallace, J A Sparks

- 1750** Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study

D Mrak, E Simader, D Sieghart, P Mandl, H Radner, T Perkmann, H Haslacher, M Mayer, M Koblichke, P Hofer, L Göschl, F Kartnig, T Deimel, A Kerschbaumer, T Hummel, B Kornek, R Thalhammer, K Stiasny, S Winkler, J S Smolen, J H Aberle, D Aletaha, L X Heinz, M Bonelli

- 1757** Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

E W Stalman, L Wieske, K P J van Dam, L Y Kummer, Z L E van Kempen, J Killestein, A G Volkers, S W Tas, L Boekel, G J Wolhink, A J Van der Kooij, J Raaphorst, M Löwenberg, R B Takekenberg, G R A M D'Haens, P I Spuls, M W Bekkenk, A H Musters, N F Post, A L Bosma, M L Hilhorst, Y Vegting, F J Bemelman, A E Voskuyl, B Broens, A Para Sanchez, C A C M van Els, J D Wit, A Rutgers, K de Leeuw, B Horváth, J J G M Verschuuren, A M Ruiter, L van Ouwkerke, D van der Woude, C F Allaart, O Y K Teng, P van Paassen, M H Busch, P B P Jallah, E Brusse, P A van Doorn, A E Baars, D J Hijnen, C R G Schreurs, W L Van der Pol, H S Goede, M Steenhuis, S Keijzer, J B D Keijser, A Boogaard, O Cristianawati, A ten Brinke, N J M Versteegen, K A H Zwinderman, T Rispens, S M van Ham, T W Kuijpers, F Efimov, On behalf of the T2B! immunity against SARS-CoV-2 study group

EULAR news

- 1767** News from EULAR
EULAR Communications

Letters

- 1768** Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink
A Abhishek, E Cipolletta, G Nakajero, A J Avery, M Mamas, L J Tata
- 1769** Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
A Bettioli, M L Urban, F Bello, D Fiori, I Mattioli, G Lopalco, F Iannone, A Egan, L Dagna, M Caminati, S Negrini, E Bargagli, M Folci, F Franceschini, R Padoan, O Flossmann, R Solans, J Schroeder, M André, L Moi, P Parronchi, D Roccatello, S Sciascia, D Jayne, D Prisco, A Vaglio, G Emmi, on behalf of the European EGPA Study Group

Electronic pages

- e239** Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort'
M J Ventura, E Guajardo, E H Clark, K Bhairavarasu, R Y Kherallah, A R DiNardo, X Ye, P A Piedra, R L Atmar, S K Agarwal
- e240** Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Ventura *et al*'
J Chommeloux, M Pouletty, N Ouldali, M Kerneis, A Mathian, R Mestiri, J Rohmer, G Hekimian, I Melki, Great Paris Region (GPR) Kawa-COVID-19 consortium
- e241** Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'
F Jeny, R Lhote, G Lorillon, N Belhomme, G Pugnet, R Borie, A Justet, S Jouneau, N Freymond, A Mekinian, R Dhote, Y Tandjaoui-Lambiotte, N Saindenberg, P Gazengel, B Hervier, J Haroche, A Mathian, M Hié, T Chazal, D Taieb, Y Uzunhan, J Le Pavec, I Annesi-Maesano, E Bergot, A Tazi, Z Amoura, D Valeyre, H Nunes, F Cohen-Aubart

- e242** Response to: 'Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'' by Jeny *et al*
A H Györfi, G Schett, J H W Distler
- e243** Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'
B-Y Wu, C-H Chan, J C-C Wei
- e244** Response to: 'Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'' by Wu *et al*
J L Pablos, M Galindo, R Blanco, J M Alvaro-Gracia
- e245** No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany)
P Aries, C Iking-Konert
- e246** Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis'
C Xu
- e247** Response to: 'Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis'' by Xu
C C Mok
- e248** Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'
Z Zhou, F Wang, Y Sun, J Teng, H Liu, X Cheng, Y Su, H Shi, Y You, C Yang, J Ye
- e249** Response to: 'Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults' by Zhou *et al*
M G Tektonidou, A Tincani, M M Ward
- e250** Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial'
M Bredemeier
- e251** Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial'' by Bredemeier
J R Seibold, V Kohlbrenner, M Alves, O Distler
- e252** Correspondence on 'Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence'
Z-L Zhang, W Huang, G-H Lv, J Li, M-X Zou, Z-H Dai
- e253** Response to 'Correspondence on "Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence" by Zhang *et al*
B S Koo, J S Oh, S Y Park, J H Shin, G Y Ahn, S Lee, K B Joo, T-H Kim
- e254** Correspondence to 'Normal human entheses harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression'
L-T Wang, K S-K Ma
- e255** Response to: 'Correspondence to 'Normal human entheses harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression' by Wang and Ma
A Wataid, C Bridgewood, D G McGonagle
- e256** Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'
H Satus, E Aydemir, K Izmirlioglu, A Tufan
- e257** Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis *et al*
S Ozen, F De Benedetti
- e258** Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'
H Wang, L Niu
- e259** Response to 'Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'' by Wang and Niu
P He, H Zhu, L-F Wu, F-Y Deng, S-F Lei
- e260** Role of interaction between B cells and epithelial cells in pSS
S Pringle, G M Verstappen, H Bootsma, F G M Kroese
- e261** Response to: 'Role of interaction between B cells and epithelial cells in pSS' by Pringle *et al*
E Rivière, X Mariette, G Nocturne
- e262** Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
R Watanabe, M Hashimoto
- e263** Management of immune checkpoint inhibitor-induced polymyalgia rheumatica
K S M van der Geest, M Sandovici, A Rutgers, T J N Hilteermann, S F Oosting, R H J A Slart, E Brouwer